For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
MOTS-c
Metabolic & Longevity Peptide
Dosage
Quantity
Price
$34.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- MOTS-c 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Educational reference from preclinical and early clinical reporting. Human data for native MOTS-c is limited; analog programs (e.g. CB4211) are often cited. Not FDA approved for therapeutic use.
Development landscape
Where the literature sits
- Discovery lineage
- Pinchas Cohen group, USC (2015)
- Primary research themes
- Exercise mimetic, longevity biology
- Analog in trials
- CB4211 — NAFLD-focused development
- Product status
- Research compound only
Trial updates are typically indexed on ClinicalTrials.gov for analog programs.
16 aa
Peptide length
Mitochondrial-derived open reading frame peptide discussed in discovery literature.
AMPK
Metabolic switch
Central kinase axis frequently linked to MOTS-c biology in preclinical models.
2×
Running endurance
Aged-mouse models: roughly doubled running time vs controls in reported protocols.
11.9×
Muscle expression
Post-exercise induction magnitude cited in muscle-focused reports.
6.4%
Median lifespan
Median lifespan shift in aged-mouse cohort summaries (preclinical).
Exercise mimetic signal
Aged-mouse performance
Reports in ~22–23.5 month animals describe large gains in treadmill performance versus untreated controls.
Relative bar illustration (treated vs control)
Model outcomes
Frequently cited preclinical endpoints
MRSA cohorts often cite ~20% survival in untreated groups vs higher survival with MOTS-c protocols in the same reports—interpret with study-specific methods.
Metabolic readouts (preclinical)
Marker summaries from mouse work
- Insulin sensitivity (aged models)Restored in reported designs
- Body weight on high-fat diet~85% of control weight
- Fat oxidationUp to ~140% vs baseline in reports
Human translation is not assumed: CB4211 Phase 1a focused on safety/tolerability; Phase 1b targets NAFLD signals.
Max lifespan
↑ ~7%
Aged mice — Reynolds et al., 2021.
Vascular calcification
↓ ~55%
Wei et al., 2020.
MRSA survival
Up to 100%
Post-infection treatment context in reports.
NAFLD activity (analog)
↓ ~33%
CB4211 sponsor/data disclosures (verify primary source).
Cardiovascular
Endothelium & calcification
Plasma MOTS-c has been correlated with endothelial function; treatment models report less vascular calcification.
Metabolism
Flexibility & pediatric signal
- Glucose uptake — enhanced in model systems
- Fat oxidation — increased
- Insulin sensitivity — restored in aged-animal designs
- High-fat weight gain — attenuated
Human plasma: Obese pediatric cohorts showed ~16% lower MOTS-c vs controls (472.61 vs 561.64 ng/mL) with BMI/insulin resistance correlations — Lee et al., Cell Metab 2015.
Bone
Osteoporosis models
Ovariectomized mice: less bone loss with altered osteoclast balance and pro-repair signaling in summaries.
Ming et al., 2016.
Immune function
Infection resistance (preclinical)
MRSA models describe improved survival and macrophage bactericidal capacity with MOTS-c exposure in published protocols.
- Pretreatment survival
- 20% → 79%
- Post-infection treatment survival
- 50% → 100%
- Bacterial burden
- Reduced
- Pro-inflammatory cytokines
- Dampened
ADDF Cognitive Vitality Report (context for MRSA summaries)
Safety profile from research
Preclinical plus limited early human analog data.
Commonly cited mild events
Fatigue (transient)
MildNausea
MildHeadache
MildInjection site
MildSex-dependent biology
- Males may show greater metabolic vulnerability when MOTS-c signaling is low.
- Pre-menopausal estrogen context may modify responses in some reports.
- Dose-response and efficacy could differ by sex—protocol-specific.
Analog & interaction notes
- CB4211: 7-day Phase 1a described as safe and tolerable in healthy volunteers.
- Preclinical packages rarely report serious adverse events in published summaries.
- Possible overlap with AMPK-activating drugs (e.g. metformin)—review concomitant use carefully.
Typical research exclusions / flags
- Possible interaction with anti-diabetic stacks in translational planning.
- Long-term human effects of native peptide remain sparsely characterized.
- Cell-culture work notes SASP modulation—interpret preclinical context only.
Storage handling reference
Peptide handling
Cold chain
Store lyophilized peptide cold.
Desiccated
Limit moisture exposure.
Light
Minimize light when possible.
Reconstitution
Prepare solutions per SOP.
Researcher notes
- Human safety depth today is largely tied to engineered analogs (e.g. CB4211), not endogenous MOTS-c dosing.
- Mouse datasets generally describe a favorable acute safety window in published protocols.
- Effects in the literature often stand out most in metabolically stressed or aged model systems.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.